Treatment

Choosing therapies based on mechanism, severity, and goals

Treatments that block complement-mediated hemolysis

Therapies that target the underlying B-cell clone

How clinicians decide when intervention is warranted

Adapting treatment over time as conditions change

Measures that reduce symptoms and prevent hemolytic triggers

Aligning treatment choices with patient priorities

Limits of algorithms in individualized clinical decisions

Where evidence ends and judgment begins

Watch Dr. Catherine Broome review the CARDINAL and CADENZA trials and how C1s inhibition reduces hemolysis, transfusion burden, and fatigue

Watch Prof. Marc Michel review rituximab-based regimens and emerging therapies targeting the clonal B-cell disorder underlying CAD

Watch Dr. Ilene C. Weitz explain how agglutination and complement-mediated hemolysis drive distinct symptoms and guide treatment selection